Literature DB >> 10532775

Comitant esodeviation resulting from neurologic insult in children.

G T Liu1, R W Hertle, G E Quinn, D B Schaffer.   

Abstract

PURPOSE: Our purpose was to establish whether comitance was a common or uncommon finding in children with esodeviation associated with a neurologic insult.
METHODS: A retrospective chart review was performed of children with acquired esodeviation associated with an identifiable neurologic insult.
RESULTS: Examinations of 30 children seen over a 2-year period were analyzed. Twenty-two (73%) had brain tumors. Twelve (40%) had comitant esodeviation, and the other 18 (60%) had incomitant measurements. Of the patients with comitant esodeviation, 6 had normal abduction OU (two after recovery from bilateral sixth nerve palsies), and 6 had mild or minimal abduction deficits. Moderate or severe abduction deficits were associated with incomitant measurements.
CONCLUSIONS: Comitant esodeviation can be common in children with identifiable neurologic insults.

Entities:  

Mesh:

Year:  1997        PMID: 10532775     DOI: 10.1016/s1091-8531(97)90055-0

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  4 in total

Review 1.  Disorders of Vergence Eye Movements.

Authors:  Anthony J Brune; Eric R Eggenberger
Journal:  Curr Treat Options Neurol       Date:  2018-08-23       Impact factor: 3.598

2.  Acute Acquired Comitant Esotropia in Adults: Is It Neurologic or Not?

Authors:  Kadriye Erkan Turan; Tulay Kansu
Journal:  J Ophthalmol       Date:  2016-11-27       Impact factor: 1.909

3.  Acute comitant esotropia in a child with a cerebellar tumor.

Authors:  Jong-Min Lee; Sin-Hoo Kim; Jeong-Il Lee; Ji-Yong Ryou; Sook-Young Kim
Journal:  Korean J Ophthalmol       Date:  2009-09-09

4.  Acute Acquired Concomitant Esotropia: Clinical features, Classification, and Etiology.

Authors:  Jingchang Chen; Daming Deng; Yuan Sun; Tao Shen; Guobin Cao; Jianhua Yan; Qiwen Chen; Xuelian Ye
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.